SynthesisPharmacoEconomics2005

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Peter K Schädlich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.